Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Persistent Epithelial Defect Management Market?
The market size of persistent epithelial defect management has witnessed significant expansion in the past few years. An upsurge from $7.92 billion in 2024 to $9.29 billion in 2025, with a compound annual growth rate (CAGR) of 17.3%, is expected. The growth trajectories observed during the historical period are due to enhanced research endeavors, escalated demand in hospitals, a rise in ocular surface disorders, an increase in eye ailments, and an aging demographic.
What Growth Rate Is Forecasted for the Persistent Epithelial Defect Management Market by 2029?
The market for managing persistent epithelial defects is predicted to experience speedy expansion in the upcoming years. It is projected to reach a whopping $17.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.9%. The surge in this timeframe is attributed to an intensification of partnerships and collaborations, heightened awareness and education, a leaning towards value-based care, and escalating incidence of conditions like diabetes and hypertension, along with timely intervention and management. Pertinent trends in this projection period encompass technological progressions, a growing demand for revolutionary treatment methods, advanced treatment modalities, the accessibility of advanced surgical instruments and techniques, and cutting-edge drugs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21256&type=smp
Which Key Companies Are Shaping the Future of the Persistent Epithelial Defect Management Market?
Major companies operating in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompé Farmaceutici S.p.A., Lumenis Ltd., TissueTech Inc., Ocular Therapeutix Inc., Oculus Surgical Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc.
Which Factors Are Driving Demand in the Persistent Epithelial Defect Management Industry?
The growth of the market for managing persistent epithelial defects is likely to be fueled by the rising prevalence of eye disorders. These disorders denote an array of health issues impacting the structure, functionality, or wellbeing of the eyes, which could lead to discomfort, impaired vision, or even complete loss of sight. It is the surge in the aging population, extended screen exposure, and shifts in the environment that are responsible for the escalating occurrence of eye disorders. It is crucial to manage persistent epithelial defects in treatment as it aids in promoting healing, reducing inflammation, and warding off complications like infection or scarring. To illustrate, the World Health Organization, an intergovernmental organization based in Switzerland, disclosed in December 2024 that the overall incidence of myopia in children was 5.23% in 2023, with it being noticeably higher in girls (4.90%) versus boys (3.94%). Hence, the climbing incidence of eye conditions is spurring the growth of the market for management of persistent epithelial defects. The escalating number of eye surgeries are projected to drive the persistent epithelial defect management market’s growth in the future. Eye surgeries include medical interventions done on the eye for rectifying vision issues, addressing diseases, or mending injuries. The surge in eye surgeries can be ascribed to the rising prevalence of eye disorders like cataracts, glaucoma, and refractive errors, advancements in surgical tactics, and a growing preference for less invasive procedures. The management of persistent epithelial defects enhances eye surgeries by encouraging healing of the cornea, curbing complications, and ameliorating vision outcomes via targeted treatments facilitating epithelial regeneration. For instance, in 2023, the Eye Bank Association of America, a US- based transplant association, reported that domestic keratoplasty procedures witnessed a 2.7% growth, climbing from 49,597 in 2022 to 50,925 in 2023. Thus, the upturn in eye surgeries is pushing the growth of the persistent epithelial defect management market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21256&type=smp
How Is the Persistent Epithelial Defect Management Market Segmented by Several Divisions?
The persistent epithelial defect management market covered in this report is segmented –
1) By Disease Type: Epithalial Or Limbal, Inflammatory Disease, Neurotrophic Disease, Other Disease Types
2) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Hospitals
3) By End User: Hospital Or Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users
Subsegments:
1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD), Limbal Transplantation, Conjunctival Transplantation
2) By Inflammatory Disease: Dry Eye Syndrome, Allergic Conjunctivitis, Uveitis
3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis, Diabetic Neuropathy, Neurotrophic Keratopathy
4) By Other Disease Types: Chemical Burns, Trauma-Induced Defects, Congenital Corneal Opacities
What are the Emerging Market Trends Driving the Growth of the Persistent Epithelial Defect Management Industry?
Leading firms in the persistent epithelial defect management market are centering their efforts on the creation of novel therapies like secretome therapy, intending to quicken recovery and enhance health outcomes for those suffering from persistent epithelial defects. Secretome therapy entails the utilization of bioactive molecules that cells secrete, such as proteins, extracellular vesicles, and lipids, in order to stimulate tissue restoration, modify immune system responses, and address various illnesses. For instance, in April 2023, U.S. biopharmaceutical company Kala Pharmaceuticals Inc. was granted the Fast Track Designation from the U.S. Food and Drug Administration (FDA) for KPI-012, which is a human MSC-S therapy for ceaseless corneal epithelial defect. This medication operates through a multifaceted mechanism that targets all root causes of persistent epithelial defect management by encouraging corneal healing using bioactive molecules like protease inhibitors, growth factors, and neurotrophic factors.
Access The Full Report Here:
Which Regions Are Driving Growth in the Persistent Epithelial Defect Management Market?
North America was the largest region in the persistent epithelial defect management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the persistent epithelial defect management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21256
This Report Delivers Insight On:
1. How big is the persistent epithelial defect management market, and how is it changing globally?
2. Who are the major companies in the persistent epithelial defect management market, and how are they performing?
3. What are the key opportunities and risks in the persistent epithelial defect management market right now?
4. Which products or customer segments are growing the most in the persistent epithelial defect management market?
5. What factors are helping or slowing down the growth of the persistent epithelial defect management market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model